Zacks Research Has Negative Forecast for Novavax Q4 Earnings

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Research analysts at Zacks Research lowered their Q4 2026 earnings estimates for shares of Novavax in a report released on Wednesday, February 26th. Zacks Research analyst S. Ganoria now anticipates that the biopharmaceutical company will post earnings per share of $0.40 for the quarter, down from their previous forecast of $0.45. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share.

A number of other research analysts have also recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. TD Cowen upgraded shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. Finally, BTIG Research assumed coverage on Novavax in a research note on Friday. They issued a "buy" rating and a $19.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $18.00.

Novavax Trading Down 2.4 %

Novavax stock traded down $0.19 during mid-day trading on Friday, reaching $7.68. The company had a trading volume of 3,969,378 shares, compared to its average volume of 4,702,457. The business has a fifty day simple moving average of $8.50 and a 200 day simple moving average of $9.91. The company has a market cap of $1.23 billion, a P/E ratio of -3.40, a P/E/G ratio of 2.85 and a beta of 2.14. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86.

Remove Ads

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same period last year, the firm posted ($1.44) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Novavax during the fourth quarter valued at approximately $27,000. Spire Wealth Management bought a new position in shares of Novavax in the 4th quarter worth $29,000. New Age Alpha Advisors LLC acquired a new stake in Novavax in the 4th quarter valued at $35,000. KBC Group NV increased its stake in Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 1,598 shares during the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Novavax

In other news, Director James F. Young sold 4,600 shares of the company's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the transaction, the director now owns 57,160 shares in the company, valued at approximately $484,716.80. This represents a 7.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rachel K. King sold 4,150 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. This trade represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 over the last quarter. Company insiders own 1.00% of the company's stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.